The effect of membrane transporters on drug disposition, efficacy and safety is now well
recognized. Since the initial publication from the International Transporter Consortium …

The Pharmacogene Variation Consortium (PharmVar) serves as a global repository
providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 …

Drug combination therapy is the most common pharmacological strategy for hypertension
management. No pharmacogenetic biomarkers for guiding hypertension pharmacotherapy …

Pharmacogenomics is the examination of how genetic variation influences drug metabolism
and response, in terms of both efficacy and safety. In cardiovascular disease, patient …

Statins are widely used medications for the primary and secondary prevention of
cardiovascular diseases. Statin-induced musculoskeletal symptoms are the primary adverse …

Organic-anion-transporting polypeptide 1B1 (OATP1B1), encoded by the solute carrier
organic anion transporter family member 1B1 gene (SLCO1B1), is highly expressed in the …

Background and aims The efficacy of statin therapy is hindered by intolerance to the therapy,
leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter …

Pitavastatin, a potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is indicated
for the treatment of hypercholesterolemia and mixed dyslipidemia. Hepatic uptake of …

Aim: To evaluate the association between SLCO1B1 polymorphisms and
elimination/toxicities of high-dose methotrexate (MTX). Methods: SLCO1B1 rs11045879 and …

Organic anion transporting polypeptides (OATPs) are membrane proteins that mediate the
uptake of a wide range of substrates across the plasma membrane of various cells and …